Research programme: cell signalling cancer therapeutics - Echelon Biosciences
Latest Information Update: 16 Jan 2008
At a glance
- Originator Echelon Biosciences; University of Texas M. D. Anderson Cancer Center
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Jan 2005 Echelon Biosciences has been acquired by AEterna Zentaris
- 22 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)